Metraipolis › archive › dc_02dbc4802a32
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications — Europe PMC PMID:42137787
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42137787
- DOI
- 10.1210/jendso/bvag082
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T12:33:28.757Z
- SHA-256 of the archived text
025dd6e2c51860e03f98da28a5128ceb28baf5fd857fb1ec438f9426bce0ff50- Stable URL of this page
https://metraipolis.com/documento/dc_02dbc4802a32
How to cite
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications — Europe PMC PMID:42137787 — Europe PMC (en), https://europepmc.org/article/MED/42137787 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_02dbc4802a32 (Metraipolis archive dc_02dbc4802a32, sha256 025dd6e2c51860e03f98da28a5128ceb28baf5fd857fb1ec438f9426bce0ff50)
BibTeX
@misc{dc02dbc4802a32,
title = {Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications — Europe PMC PMID:42137787},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42137787},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_02dbc4802a32; sha256 025dd6e2c51860e03f98da28a5128ceb28baf5fd857fb1ec438f9426bce0ff50},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42137787. Agents can read the archived copy with the MCP tool read_document.